iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/39075953/
Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;30(33):2587-2596.
doi: 10.2174/0113816128309913240704095334.

Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression

Affiliations
Review

Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression

Ashish Suresh Patil et al. Curr Pharm Des. 2024.

Abstract

The purpose of this review is to correlate the probable causes of anxiety disorders with the imbalance of neurotransmitters in the brain and also highlight the drugs for these mental disorders that have been discovered based on the biosynthesis and catabolism of these brain chemicals. Peer-reviewed journal's articles, news and books published in English between 1997 and 2023 describing the role of neurotransmitters in anxiety disorders were searched in Google Scholar, Research Gate and PubMed databases. The contents were carefully analyzed by the authors and understood and compiled to build a concise perspective on the role of biosynthesis and catabolism of neurotransmitters in anxiety and depression. Anxiety disorders are reported to be common patterns of psychological symptoms that impact multiple areas of life. Anxiety and depression are prevalent worldwide and are significantly contributing towards the global health burden. Genetic determinants are believed to play an important role in these disorders. According to modern medicine, one of the most important aspects that is known to be crucial for these disorders is the imbalance of neurotransmitters in the brain. The biosynthesis and catabolism of neurotransmitters have been extensively targeted for innovative drug discovery approaches at various steps that have led to the discovery of many drugs for these psychological disorders. The biosynthetic and catabolic reaction cycles of neurotransmitters and the discovery of drugs based on these hypotheses are discussed. To the best of the authors' knowledge, this review compiles already known descriptive knowledge on "relation of neurotransmitter imbalance with anxiety disorders" in a precise way that will provide readers with an overview of the vast literature.

Keywords: Anxiety disorders; biosynthesis; catabolism; depression; drug discovery.; neurotransmitters.

PubMed Disclaimer

Similar articles

References

    1. Kessler R.C.; Chiu W.T.; Demler O.; Walters E.E.; Walters E.E.; Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005,62(6),617-627 - DOI - PubMed
    1. Bhatt N.V.; Baker M.J.; Jain V.B.; Anxiety Disorders. Available from: https://emedicine.medscape.com/article/286227- overview2019
    1. Vahia VN. American Psychiatric Association. Cautionary statement for forensic use of DSM-5. Diagnostic and statistical manual of mental disorders. 2013. - DOI
    1. Santomauro D.F.; Mantilla Herrera A.M.; Shadid J.; Zheng P.; Ashbaugh C.; Pigott D.M.; Abbafati C.; Adolph C.; Amlag J.O.; Aravkin A.Y.; Bang-Jensen B.L.; Bertolacci G.J.; Bloom S.S.; Castellano R.; Castro E.; Chakrabarti S.; Chattopadhyay J.; Cogen R.M.; Collins J.K.; Dai X.; Dangel W.J.; Dapper C.; Deen A.; Erickson M.; Ewald S.B.; Flaxman A.D.; Frostad J.J.; Fullman N.; Giles J.R.; Giref A.Z.; Guo G.; He J.; Helak M.; Hulland E.N.; Idrisov B.; Lindstrom A.; Linebarger E.; Lotufo P.A.; Lozano R.; Magistro B.; Malta D.C.; Månsson J.C.; Marinho F.; Mokdad A.H.; Monasta L.; Naik P.; Nomura S.; O’Halloran J.K.; Ostroff S.M.; Pasovic M.; Penberthy L.; Reiner R.C.; Reinke G.; Ribeiro A.L.P.; Sholokhov A.; Sorensen R.J.D.; Varavikova E.; Vo A.T.; Walcott R.; Watson S.; Wiysonge C.S.; Zigler B.; Hay S.I.; Vos T.; Murray C.J.L.; Whiteford H.A.; Ferrari A.J.; Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021,398(10312),1700-1712 - DOI - PubMed
    1. Nasir M.; Trujillo D.; Levine J.; Dwyer J.B.; Rupp Z.W.; Bloch M.H.; Glutamate systems in DSM-5 anxiety disorders: Their role and a review of glutamate and GABA psychopharmacology. Front Psychiatry 2020,11,548505 - DOI - PubMed

MeSH terms

LinkOut - more resources